17 Aug From facial microbiome maps to actionable skin health insights: what a new JID publication shows about PMP™ 

DSM-Firmenich, together with Bio-Me as co-authoring partner, has published a new proof-of-concept study in the Journal of Investigative Dermatology, introducing a 3D facial skin microbiome mapping approach built on Bio-Me’s Precision Microbiome Profiling (PMP™) platform, integrating absolute microbial quantification with spatial interpolation.

OSLO, Norway, August 17, 2026 – Skin microbiome science is moving rapidly from exploration toward application. For ingredient manufacturers, dermo-cosmetic developers and skincare brands, the key question is no longer simply whether the skin microbiome matters. It is how to measure it in a way that supports robust, quantitative and product-relevant insights.

A new proof-of-concept publication in the Journal of Investigative Dermatology, initiated and led by DSM-Firmenich with Bio-Me as a co-authoring partner, provides a strong example of what this can look like in practice. The study presents a 3D facial skin microbiome mapping approach that integrates absolute microbial quantification with spatial interpolation, enabling continuous visualization of bacterial and fungal distributions across the face.

For team Bio-Me, this publication validates our core thesis: when advanced skin microbiome research is built on high-quality quantitative data, clients can generate more ambitious, more interpretable and more actionable insights.

What the study accomplished

The authors set out to move beyond skin microbiome studies that rely on relative-abundance data from limited sampling sites. Instead, they combined multi-site facial sampling, absolute microbial quantification and 3D spatial interpolation to visualize how microbial community composition shifts across the face with high spatial resolution.

The study revealed a marked topographical heterogeneity in core microbial species. For example, the authors reported distinct facial distribution patterns for Cutibacterium acnes and Malassezia restricta, including an inverse association between C. acnes abundance and microbial diversity across much of the face, as well as a forehead-specific pattern involving M. restricta.

According to the authors, this approach can help identify site-specific dysbioses, guide targeted interventions and track treatment effects, thereby linking microbial biogeography more directly to applied dermatology and skin health.

At Bio-Me, we are proud to see PMP™ supporting this type of client-led innovation. The publication is a strong example of what becomes possible when skin microbiome research is built on accurate, sensitive, reproducible and scalable absolute microbial quantification.

Why this matters for ingredient and skincare innovation

For ingredient innovators such as DSM-Firmenich, the value of this work resides in the ability to generate differentiated, quantitative evidence around product-relevant mechanisms rooted in skin biology and microbial ecology. This matters because facial skin is not microbiologically uniform. Local differences in sebum, hydration, barrier function and microenvironment can shape microbial ecology. A product effect measured at one facial site may not fully represent what happens elsewhere. Understanding those local patterns can help companies design better studies and interpret product effects more meaningfully.

Ingredient manufacturers increasingly need to show how ingredients interact with real skin biology, including the microbiome. Quantitative microbiome profiling can help answer critical R&D questions:

• Which microbial taxa are affected?
• Are changes site-specific?
• Are shifts measurable in absolute terms (microbial load)?
• Can effects be followed over time?
• Can the data support mechanism-of-action work or study design?
• Can the data substantiate product claims for efficacy or microbiome safety?

For skincare developers and brand owners, the same logic applies. Microbiome-related product concepts are becoming more sophisticated and therefore require stronger data. Spatially informed quantitative microbiome profiling can support better sampling strategies, more targeted product evaluation and more credible evidence generation.

How PMP™ contributed

In the study, absolute abundances of 35 microbial species and genera were determined using Bio-Me’s quantitative PCR-based platform for Precision Microbiome Profiling (PMP™). These absolute abundance measurements formed the quantitative microbial data layer used in the 3D mapping workflow. The study also validated once again the quantitative accuracy of the PMP™ platform by confirming results using droplet digital PCR.

Why PMP™ is relevant for skin microbiome studies

Skin microbiome analysis is technically demanding. Skin samples often contain low microbial biomass and substantial human background DNA, making it difficult to generate robust, cost-effective, and reproducible data with conventional approaches.

PMP™ is designed for targeted, quantitative analysis of well-defined microbial taxa. Its characteristics are particularly relevant for commercial skin, scalp and intimate care R&D:

• Absolute quantification helps determine whether specific microbial targets truly increase, decrease or remain stable.
• Quantitative accuracy supports mechanism-of-action studies, dose-response evaluation, longitudinal monitoring and product claim substantiation.
• Sensitivity is essential for low-biomass sample types such as skin swabs and tape strips.
• Precision and reproducibility help to keep study size and cost in check by ensuring that differences observed across sites, subjects, timepoints, and study arms are interpretable.
• Fast turnaround and scalability support ever accelerating product lifecycles and make microbiome testing more practical for ingredient screening, larger cohort studies and longitudinal study designs.

Together, these characteristics make PMP™ a strong analytical foundation for companies that require speed and precision for microbiome data that inform real product decisions.

Interested in applying PMP™ to your next skin, scalp or intimate care study?
Contact Bio-Me to discuss how quantitative microbiome profiling can support ingredient screening, product development, claim substantiation and longitudinal microbiome research.